by Stacey Hawkins | Apr 24, 2019 | Front Page Feature
Coming Soon? A New Biologic For the past two decades, monoclonal antibodies (mAbs) have dominated the biologic drugs market. Doctors use these blockbuster products for a range of diseases, including many cancers and autoimmune diseases. In addition to their... 
by Stacey Hawkins | Oct 8, 2015 | Genomics, Uncategorized
DNA: Coding Vs. NON-Coding The completion of the Human Genome Project in 2003 revealed a big surprise: up to 98% of the DNA making up the human genome does not code for proteins! The notion that parts of the genome were non-coding had been circulating for several... 
by Stacey Hawkins | Jan 15, 2015 | Regulation
Last week, the FDA’s Oncologic Drugs Advisory Committee unanimously recommended Novartis’ biosimilar version of Amgen’s megahit Neupogen (filgrastim), effectively paving the way for the first US biosimilar approval in the near future. Filgrastim is a...
